Thrombosis

Research Article

Reversible Crystallization of Argatroban after Subcutaneous Application in Pigs

Table 2

Pharmacokinetic parameters of argatroban in pigs after single subcutaneous doses of 0.5 or 2 mg·kg−1 of the sorbitol/ethanol formulation. Values are the mean of 𝑛 = 5 , showing the standard deviation. * 𝑃 < 0 . 0 5 ; ** 𝑃 < 0 . 0 1 .
 Argatroban dose
 0.5 mg·kg−12 mg·kg−1
𝑡 1 / 2 𝛽 (h) 1 4 . 4 6 ± 3 . 9 1 1 6 . 4 6 ± 3 . 9 6
𝐶 m a x (μg·mL−1) 1 . 0 7 ± 0 . 1 3 2 . 5 9 ± 0 . 4 2 ∗
𝑡 m a x (h) 3 . 8 0 ± 1 . 3 0 4 . 2 5 ± 0 . 5 0
AUC0–24 (μg·mL−1·h) 1 4 . 3 4 ± 2 . 4 2 4 0 . 7 6 ± 5 . 1 2 ∗ ∗
𝑡 1 / 2 𝛽 : elimination half-life; 𝐶 m a x : maximum concentration to 𝑡 m a x ; 𝑡 m a x : time of maximum concentration; AUC0–24: area under the concentration-time curve from 0 to 24 hours.